Enlaza Therapeutics

Enlaza Therapeutics is a pioneer in the field of covalent biologics. These novel protein therapies offer patients more effective and safer treatments. The company's proprietary War-LockTM platform leverages cutting-edge synthetic biology technology to enable drug conjugation-driven site-specific covalent coupling. Enlaza is creating a groundbreaking new class of protein therapies that provide patients with more effective and safer treatment options. Enlaza’s breakthrough WarLockTM technology enables the creation of unique, highly selective biologics designed as warheads that irreversibly lock onto disease-associated targets. We utilize our novel synthetic biology platform, along with proprietary amino acids, to precisely engineer biologics that enhance efficacy and safety.